AlterG builds technology for physical rehabilitation, training, and wellness. The company's products, the Anti-Gravity Treadmills, and the AlterG Bionic Leg, are designed for personal mobility and wellness. Its Anti-Gravity Treadmills use Differential Air Pressure (DAP) technology, developed at NASA. The Bionic Leg, designed for patients with neurological and orthopedic gait disorders, is a robotic assistive device that is activated by patient-initiated movement and provides stability and assistance for a range of mobility training. The company was founded in 2004 and is based in Fremont, California In August 2023, AlterG was acquired by ReWalk Robotics
Expert Collections containing AlterG
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AlterG is included in 1 Expert Collection, including Robotics.
This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.
AlterG has filed 34 patents.
Gait abnormalities, Walking, Terrestrial locomotion, Parkinson's disease, Rare diseases
Gait abnormalities, Walking, Terrestrial locomotion, Parkinson's disease, Rare diseases
Latest AlterG News
Jan 12, 2024
January 12, 2024 08:30 ET ReWalk Robotics Ltd. MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. ( Nasdaq: RWLK ) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, announced today that the Company is expanding its direct sales coverage to Canada. This expansion occurs as the result of the integration between the former ReWalk and AlterG commercial teams following the recent acquisition, which has resulted in a more extensive sales force with increased capacity. “With the formation of our larger, newly combined commercial team, we have expanded three sales territories to include the major population centers in Canada,” said Larry Jasinski, Chief Executive Officer of ReWalk. “We believe that the Canadian market for Anti-Gravity systems has been underserved in the past, and we anticipate that our expanded direct sales presence will allow the Company to penetrate these markets more effectively.” “The integration of AlterG and ReWalk continues to make great progress,” continued Mr. Jasinski. “In addition to the restructuring of our commercial teams, each of our functional areas has been realigned into our new operating structure. We believe that this integration will result in faster growth and a leaner cost structure, in line with our objectives to achieve profitability funded solely through our existing cash resources.” About ReWalk Robotics Ltd. ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com . For more information on the AlterG systems, please visit alterg.com. ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. Alter G® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions. Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s ability to realize the anticipated benefits of the acquisition of AlterG, including the possibility that the expected benefits of the acquisition will not be realized within the expected time period or at all; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; ReWalk's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; ReWalk's ability to regain and maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk’s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk's ability to achieve adequate reimbursement from third-party payors, including CMS, for its products; ReWalk's limited operating history and its ability to leverage its sales, marketing and training infrastructure; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; ReWalk's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; ReWalk's ability to improve its products and develop new products; ReWalk's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on ReWalk's ability to market and sell its products; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; ReWalk's ability to use effectively the proceeds of its offerings of securities; ReWalk’s ability to reduce operating expenses; and other factors discussed under the heading "Risk Factors" in ReWalk's annual report on Forms 10-K and 10-K/A for the year ended December 31, 2022 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. ReWalk Investor Contact:
AlterG Frequently Asked Questions (FAQ)
When was AlterG founded?
AlterG was founded in 2004.
Where is AlterG's headquarters?
AlterG's headquarters is located at 48368 Milmont Drive, Fremont.
What is AlterG's latest funding round?
AlterG's latest funding round is Acquired.
How much did AlterG raise?
AlterG raised a total of $51.95M.
Who are the investors of AlterG?
Investors of AlterG include Lifeward, Cortland Credit Lending Corporation, Versant Ventures, Silicon Valley Bank, Oxford Finance and 8 more.
Who are AlterG's competitors?
Competitors of AlterG include ComeBack Mobility, Keystone Dental, Mercator MedSystems, Netpulse, Magneceutical Health and 7 more.
Compare AlterG to Competitors
Mercator MedSystems is a medical technology company that focuses on the treatment of peripheral artery disease. The company offers catheter-guided, microfluid injection systems for site-specific, non-systemic delivery of therapeutic agents directly across any blood vessel, providing efficient and targeted treatment for vascular diseases. The technology also finds application in the treatment of hypertension, oncology, and regenerative medicine. Mercator MedSystems was formerly known as EndoBionics. It was founded in 1999 and is based in Emeryville, California.
Dornier MedTech is a leading company in the urological medical device industry, focusing on the development and provision of innovative urology care solutions. The company offers a range of products including shock wave lithotripsy devices, laser systems, endoscopes, and urology workstations designed to treat various urological conditions in a clinical setting. Dornier MedTech also provides digital platforms to support patient care and community engagement in the field of urology. It is based in Kennesaw, Georgia.
Navotek Medical is a developer of the proprietary RealTrack intra-body tracking technology
Advanced Medical Diagnostics appoints Imaging Equipment Ltd as commercial agent for Prostate HistoScanning in the UK and Ireland.
Catheter Connections develops vascular access products that can help protect patients from life-threatening infections during infusion therapy. The company's flagship product, DualCap, a sterile, single-use device containing two disinfecting caps - one for the IV catheter needleless luer access valve (also known as the needleless injection site, port or valve) and one for the male luer connector at the end of the IV tubing - is an FDA-cleared device for disinfection and protection of both the IV catheter needleless luer access valve and the male luer connector at the end of the IV tubing. DualCap helps to prevent intraluminal contamination, the most common way IV connectors contribute to infections in long-term catheter use.
Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.